Frederike G I van Vilsteren
Overview
Explore the profile of Frederike G I van Vilsteren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trillos-Almanza M, Aguilar M, Buist-Homan M, Bomer N, Gomez K, de Meijer V, et al.
Mol Biol Rep
. 2024 Nov;
51(1):1116.
PMID: 39495311
Background: End-stage liver diseases (ESLDs) are a significant global health challenge due to their high prevalence and severe health impacts. Despite the severe outcomes associated with ESLDs, therapeutic options remain...
2.
Oerbekke M, de Man R, van Vilsteren F, Nijkamp M, Tjwa E, Gaasterland C, et al.
Orphanet J Rare Dis
. 2024 Oct;
19(1):364.
PMID: 39358755
We aim to illustrate the role of complete and transparent reporting coupled with access to data sourced from published systematic reviews, especially assisting in the identification of evidence for subgroups...
3.
Meinderts J, Metselaar H, van Hoek B, den Hoed C, Rijntjes D, Groenewout M, et al.
Liver Transpl
. 2024 Sep;
PMID: 39250125
Pregnancy after orthotopic liver transplantation (OLT) puts the mother, child, and transplanted organ at risk. Little is known about long-term outcomes. We performed a nationwide retrospective cohort study to evaluate...
4.
Mackay T, Latenstein A, Augustinus S, van der Geest L, Bogte A, Bonsing B, et al.
JAMA Surg
. 2024 Feb;
159(4):429-437.
PMID: 38353966
Importance: Implementation of new cancer treatment strategies as recommended by evidence-based guidelines is often slow and suboptimal. Objective: To improve the implementation of guideline-based best practices in the Netherlands in...
5.
de Jong D, den Hoed C, Willemssen F, Thomeer M, Bruno M, Groot Koerkamp B, et al.
Gastrointest Endosc
. 2023 Oct;
99(4):548-556.
PMID: 37890597
Background And Aims: For a highly selected group of patients with unresectable perihilar cholangiocarcinoma (pCCA), liver transplantation (LT) is a treatment option. The Dutch screening protocol comprises nonregional lymph node...
6.
Quispel R, Schutz H, Keultjes A, Erler N, Janssen Q, van Hooft J, et al.
HPB (Oxford)
. 2023 Aug;
25(11):1438-1445.
PMID: 37550169
Introduction: Endoscopic ultrasonography guided tissue acquisition (EUS + TA) is used to provide a tissue diagnosis in patients with suspected pancreatic cancer. Key performance indicators (KPI) for these procedures are...
7.
Levink I, Jaarsma S, Koopmann B, van Riet P, Overbeek K, Meziani J, et al.
United European Gastroenterol J
. 2023 Jul;
11(7):601-611.
PMID: 37435855
Background: Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate...
8.
Hoogwater F, Kuipers H, de Meijer V, Maulat C, Muscari F, Polak W, et al.
BJS Open
. 2023 Apr;
7(2).
PMID: 37032423
Background: The Mayo protocol for liver transplantation in patients with unresectable perihilar cholangiocarcinoma is based on strict selection and neoadjuvant chemoradiotherapy. The role of neoadjuvant chemoradiotherapy in this scenario remains...
9.
Haring M, de Haas R, van Vilsteren F, Klaase J, Duiker E, Blokzijl H, et al.
Clin Res Hepatol Gastroenterol
. 2023 Feb;
47(3):102094.
PMID: 36781070
Background: Management of focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA), is multidisciplinary and subject to practice variation. We aimed to evaluate variation in clinical management of FNH and HCA...
10.
Geng Y, Arroyave-Ospina J, Buist-Homan M, Plantinga J, Olinga P, Reijngoud D, et al.
J Nutr Biochem
. 2023 Jan;
114:109255.
PMID: 36623779
Several fatty acids, in particular saturated fatty acids like palmitic acid, cause lipotoxicity in the context of non-alcoholic fatty liver disease . Unsaturated fatty acids (e.g. oleic acid) protect against...